February 26, 2026

Novo Nordisk plans major U.S. list price cuts for Ozempic and Wegovy starting January 2027 Intro Novo Nordisk says it will lower the U.S. list prices of its blockbuster GLP-1 medicines — Wegovy, Ozempic, and Rybelsus — starting January 1, 2027. The company says the goal is to reduce out-of-pocket costs for people whose payments are tied to list price, such as those with high deductibles or co-insurance. Key facts New list price target: $675 per month for Wegovy, Ozempic, and Rybelsus (effective Jan 1, 2027). This represents about a 50% cut for Wegovy (from roughly $1,349/month) and about a mid-30% cut for Ozempic (from roughly $1,028/month), per reporting and company materials. Novo says the list price change is intended to help patients whose costs are linked to list price, while noting that many insured patients may already pay lower amounts depending on their plan and programs. Novo also indicated this list-price move doesn’t necessarily change direct cash-pay offers, which companies use separately. Why does this matter? List price still matters in the U.S. because it can influence what some people pay at the pharmacy counter — especially anyone on a high-deductible plan or paying a percentage-based co-insurance rather than a flat copay. A lower list price can reduce that “sticker-shock” exposure and may also reshape negotiations across parts of the supply chain over time. The competitive context The announcement also lands in the middle of an intensifying GLP-1 market, where Novo Nordisk and Eli Lilly are both fighting for new prescriptions in obesity and diabetes care. Analysts and reporters have framed the move as part of a broader push to defend or regain momentum as demand surges and competition increases. What to watch next Plan design impact: Will insurers update formularies or cost-sharing rules as 2027 approaches? Net price vs list price: Rebates and discounts mean net prices can differ from list prices; watch what changes in real patient out-of-pocket cost. Market response: Whether Eli Lilly adjusts its strategy further or expands access programs. Sources https://www.reuters.com/ https://edition.cnn.com/ https://www.prnewswire.com/ Note: This post is an independent summary and commentary based on publicly available reporting and company statements. For full reporting, see the linked sources above